Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Mouth Neoplasms × Radiotherapy × Clear all

Phase

Phase 2 7 Phase 1 3 Phase 3 2 Phase 1/2 2 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Leukemia 5 Esophageal Squamous Cell Carcinoma 5 Esophageal Neoplasms 5 Rectal Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Oropharyngeal Neoplasms 2 Oligodendroglioma 2 Nasopharyngeal Carcinoma 2 Myelodysplastic Syndromes 2 Lymphoma 2 Lung Neoplasms 2 Leukemia, T-Cell 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myeloid, Acute 2 Leukemia, Myeloid, Accelerated Phase 2 Head and Neck Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Astrocytoma 2 Anemia, Refractory, with Excess of Blasts 2 Adenocarcinoma Of Esophagus 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Sezary Syndrome 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1

Interventions

Magnetic Resonance Spectroscopy 2 Immunoglobulin G 2 Disulfides 2 Cetuximab 2 (225)Ac-DOTA-c(RGDyK) 2 pembrolizumab 1 durvalumab 1 atezolizumab 1 acetyl-glycyl-asparagyl-glutaminyl-glutamyl-glutaminyl-valyl-seryl-prolyl-leucyl-threonyl-leucyl-leucyl-lysyl-lysyl-tryptophyl-cysteinyl-Alexa Fluoro 680 C2C2-maleimide conjugate 1 X-Rays 1 Thalidomide 1 Standard of Care 1 Specimen Handling 1 Sentinel Lymph Node Biopsy 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Radiation 1 Platinum 1 Pilocarpine 1 Photons 1 Neck Dissection 1 Fluorouracil 1 Fluorodeoxyglucose F18 1 Drug Therapy 1 Docetaxel 1 Dexamethasone 1 Cyclophosphamide 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01434394 2017-08-21

EAGLE

Shanghai Jiao Tong University School of Medicine

Phase 2/3 Completed

Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡